Platinum-(IV)-derivative satraplatin induced G2/M cell cycle perturbation via p53-p21waf1/cip1-independent pathway in human colorectal cancer cells

Acta Pharmacologica Sinica

Volumn 32, Issue 11, 2011, Pages 1387-1396

  Kalimutho, Murugan ^a   Minutolo, Antonella ^a,b   Grelli, Sandro ^a,b   Federici, Giorgio ^a   Bernardini, Sergio ^c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

14 3 3s; apoptosis; colorectal cancer; G2 M phase; p53; satraplatin

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; MESSENGER RNA; PROTEIN BCL 2; PROTEIN P53; SATRAPLATIN; STRATIFIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL STRAIN HCT116; CELL STRAIN HT29; CLONOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; WILD TYPE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA DAMAGE; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; ORGANOPLATINUM COMPOUNDS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80755163137     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.107     Document Type: Article

References (28)

1. Johnson NP, Butour JL, Villani G, Wimmer FL, Defais M, Pierson V. Metal antitumor compounds: the mechanism of action of platinum complexes. Prog Clin Biochem Med 1989; 10: 1-24.
2. Johnson SW, Ferry KV, Hamilton TC. Recent insights into platinum drug resistance in cancer. Drug Resist Update 1998; 1: 243-54.
3. Fuertes MA, Castilla J, Alonso C, Perez JM. Cisplatin biochemical mechanism of action: From cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem 2003; 10: 257-66. (Pubitemid 36131658)
4. Boulikas T, Pantos A, Bellis E, Christofis P. Designing platinum compounds in cancer: structures and mechanisms. Cancer Therapy 2007; 5: 537-83.
5. Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, et al. Preclinical antitumor evaluation of bis-acetato-ammine-dichlorocyclohexylamine platinum (IV): an orally active platinum drug. Cancer Res 1993; 53: 2581-6. (Pubitemid 23168026)
6. Sharp SY, Rogers PM, Kelland LR . Transport of cisplatin and bisacetato- ammine-dichlorocyclohexylamine platinum (IV) (JM-216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance. Clin Cancer Res 1995; 1: 981-9.
7. Choy H, Park C, Yao M. Current status and future prospects for satraplatin, an oral platinum analogue. Clin Cancer Res 2008; 14: 1633-8. (Pubitemid 351469447)
8. E lledge SJ. Cell cycle checkpoints: preventing an identity crisis. Science 1996; 274: 1664-72. (Pubitemid 26414889)
9. Bartek J, Lukas J. Pathways governing G1/S transition and their response to DNA damage. FEBS Lett 2001; 490: 117-22. (Pubitemid 32171930)
10. T aylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene 2001; 20: 1803-15. (Pubitemid 32458690)
11. L evine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-31.
12. Bunz F, Dutriaux , Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282: 1497-501. (Pubitemid 28538613)
13. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53- mediated G1 arrest in human cancer cells. Cancer Res 1995; 55: 5187-90.
14. Kalimutho M, Minutolo A, Grelli S, Formosa A, Sancesario G, Valentini A, et al. Satraplatin (JM-216) mediates G2/M cell cycle arrest and potentiates apoptosis via multiple death pathways in colorectal cancer cells thus overcoming platinum chemo-resistance. Cancer Chemother Pharmacol 2010; 67: 1299-312.
15. U KCCR. UKCCCR guidelines for the use of cell lines in cancer research. British J Cancer 2000; 82: 1495-509.
16. H an Z, Wei W, Dunaway S, Darnowski JW, Calabresi P, Sedivy J, et al. Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin. J Biol Chem 2002; 277: 17154-60. (Pubitemid 34967748)
17. Fokkema E, Groen HJM, Bauer J, Uges DRA, Weil C, Smith IE. Phase II study of oral platinum drug JM216 as first line treatment in patients with small-cell lung cancer. J Clin Oncol 1997; 17: 3822-7.
18. McKeage MJ, Mistry P, Ward J, Boxall FE, Loh S, O'Neill C, et al. A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol 1995; 36: 451-8.
19. L atif T, Wood L, Connell C, Smith DC, Vaughn D, Lebwohl D, et al. Phase II study of oral bis(acetate) ammine dichloro (cyclohexylamine) platinum (IV) (JM216, BMS-182751) given daily x n hormone refractory prostate cancer (HRPC). Invest New Drug 2005; 23: 79-84. (Pubitemid 39505954)
20. Sternberg CN, Whelan P, Hetherington J, Paluchowska B, Slee PH, Vekemans K, et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005; 68: 2-9. (Pubitemid 40675002)
21. O rmerod MG, Orr RM, Peacock JH. The role of apoptosis in cell killing by ciplatin: a flow cytometric study. Br J Cancer 1994; 69: 93-100. (Pubitemid 24021828)
22. H ermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, et al. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997; 1: 3-11. (Pubitemid 127376388)
23. Yadav SS, Sindram D, Perry DK, Clavien PA. Ischemic preconditioning protects the mouse liver by inhibition of apoptosis through a caspasedependent pathway. Hepatology 1999; 30: 1223-31. (Pubitemid 29510861)
24. R ao L, White E. Bcl-2 and the ICE family of apoptotic regulators: making a connection. Curr Opin Genet 1997; 7: 52-8. (Pubitemid 27092764)
25. R eardon JT, Vaisman A, Chaney SG, Sancar A. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine- dichlorocyclohexylamineplatinum (IV) (JM216) platinum intrastrand DN A diadducts. Cancer Res 1999; 59: 3968-71. (Pubitemid 29393563)
26. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehmé A, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996; 56: 4881-6. (Pubitemid 26374423)
27. Vaisman A, Lim SE, Patrick SM, Copeland WC, Hinkle DC, Turchi JJ, et al. Effect of DNA polymerases and high mobility group protein n the carrier ligand specificity for translesion synthesis past platinum- DNA adducts. Biochemistry 1999; 38: 11026-39.
28. Fokkema E, Groen HJ, Helder MN, de Vries EG, Meijer C. JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin. Biochem Pharmacol 2002; 63: 1989-96. (Pubitemid 34687040)